Pharma BD Deal Intelligence
Schering paid ~$140M for a cardiac gene therapy it abandoned within 3 years; the asset (Generx) never reached market under any subsequent owner, even 20+ years later.
Full analysis, sources & comparables →Peer-reviewed review of Ad5FGF-4 (Generx) describing the angiogenic mechanism, single intracoronary delivery, and ongoing Schering/Collateral late-stage…
Schering AG agreed to acquire Collateral Therapeutics in a $140M stock-for-stock transaction; Schering already held a 12% equity stake and had partnered on…
Biotech veteran Jack Reich retired in 2002 after 'selling his cardiovascular gene therapy firm Collateral Therapeutics Inc. to Schering AG in a $140 million…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Announced 2002. $140M stock-for-stock. Schering already held 12% stake. Cardiovascular gene therapy. FTC early termination granted. Tier 2 (FTC) + Tier 6 verified.
Schering paid ~$140M for a cardiac gene therapy it abandoned within 3 years; the asset (Generx) never reached market under any subsequent owner, even 20+ years later.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Schering AG / Collateral Therapeutics Inc. (this deal) | 2002 | $140M | 9 |
| Schering AG / MAP Medical Technologies Oy | 2002 | — | 26 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
← Browse all deals · How we score deals
More: 2002 deals